Document Detail

Local immune modulator (imiquimod 5% cream) as adjuvant treatment after incomplete Mohs micrographic surgery for large, mixed type basal cell carcinoma: a report of 3 cases.
MedLine Citation:
PMID:  16703785     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Surgical excision, including Mohs micrographic surgery, is the treatment of first choice for basal cell carcinoma (BCC). Occasionally, the Mohs procedure has to be ceased prematurely for unforeseen reasons. OBJECTIVE: We sought for possibilities to adjuvantly treat patients in which superficial basal cell carcinoma remained after incomplete Mohs surgery. METHODS: We report 3 cases of patients in which Mohs micrographic surgery for their large basal cell carcinomas was ceased for different unforeseen reasons, with remaining superficial fields of BCC after the aggressive and deeply localized part had been removed. Three weeks after closure of the defect, adjuvant therapy for the superficial remnants of the tumor with imiquimod 5% cream was given for 6 weeks, covering at least 1 centimeter around the surgically treated area. RESULTS: The treatment was well accepted with no serious side effects and a good cosmetic result. No recurrences were seen after a follow-up period of 20 to 34 months. CONCLUSION: A combination of surgical intervention for the central deeper part of the BCC and topical imiquimod 5% cream for the superficial part at the border might be a therapeutic option for those patients with multiple facial BCCs, severe sun damage, and extensive surgery in the past, in whom completion of the Mohs surgical procedure for the entire tumor is not possible for different reasons.
M R T M Thissen; D I M Kuijpers; G A M Krekels
Related Documents :
592885 - Lymphography in the assessment of mycosis fungoides.
7021245 - Treatment of multiple squamous cell carcinomas of the skin in an immunosuppressed patient.
22251205 - Effects of combinations of malathion and cypermethrin on survivability and time of meta...
17011445 - Accelerated partial-breast irradiation using proton beams: initial clinical experience.
25324985 - Outcome of postoperative radiotherapy following radical prostatectomy: a single institu...
2539645 - European experience with ifosfamide in non-small cell lung cancer.
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  Journal of drugs in dermatology : JDD     Volume:  5     ISSN:  1545-9616     ISO Abbreviation:  J Drugs Dermatol     Publication Date:  2006 May 
Date Detail:
Created Date:  2006-05-17     Completed Date:  2006-07-18     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101160020     Medline TA:  J Drugs Dermatol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  461-4     Citation Subset:  IM    
Department of Dermatology, University Hospital Maastricht, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Topical
Aminoquinolines / therapeutic use*
Biopsy, Needle
Carcinoma, Basal Cell / pathology*,  therapy*
Chemotherapy, Adjuvant
Follow-Up Studies
Middle Aged
Mohs Surgery / methods*
Neoplasm Staging
Risk Assessment
Skin Neoplasms / pathology*,  therapy*
Treatment Outcome
Reg. No./Substance:
0/Aminoquinolines; 0/Emollients; 99011-02-6/imiquimod

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Autosensitization dermatitis associated with propolis-induced allergic contact dermatitis.
Next Document:  Nasal reconstruction using 20 mg/ml cross-linked hyaluronic acid.